Copyright
©The Author(s) 2005.
World J Gastroenterol. Jul 21, 2005; 11(27): 4261-4267
Published online Jul 21, 2005. doi: 10.3748/wjg.v11.i27.4261
Published online Jul 21, 2005. doi: 10.3748/wjg.v11.i27.4261
Groups | D0 | D5 | D10 | P3 |
Lamivudine-susceptive DHBV control | 0.96 ± 0.31 | 1.00 ± 0.06 | 0.87 ± 0.05 | 0.87 ± 0.02 |
LRDHBV control | 0.91 ± 0.03 | 0.86 ± 0.01 | 0.95 ± 0.01 | 0.95 ± 0.04 |
LRDHBV-infected group administrated by large dose Lamivudine | 0.96 ± 0.03 | 0.94 ± 0.02 | 0.97 ± 0.05 | 0.97 ± 0.03 |
LRDHBV-infected group administrated by small dose Lamivudine | 0.96 ± 0.02 | 0.88 ± 0.02 | 0.87 ± 0.01 | 0.90 ± 0.05 |
Lamivudine-susceptive DHBV-infected group administrated by small dose Lamivudine | 0.96 ± 0.05 | 0.73 ± 0.05b | 0.22 ± 0.03b | 0.69 ± 0.02b |
- Citation: He JY, Zhu YT, Yang RY, Feng LL, Guo XB, Zhang FX, Chen HS. Mutations outside the YMDD motif in the P protein can also cause DHBV resistant to Lamivudine. World J Gastroenterol 2005; 11(27): 4261-4267
- URL: https://www.wjgnet.com/1007-9327/full/v11/i27/4261.htm
- DOI: https://dx.doi.org/10.3748/wjg.v11.i27.4261